Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfons A den Broeder

Showing results (1-10 of 166) with videos related to

Pageof 17
Sort By:
Best Practice & Research. Clinical Rheumatology|December 25, 2015
De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?Bruno Fautrel, Alfons A Den Broeder
The Journal of Rheumatology|March 2, 2021
If You Want to Perform a Cost-effectiveness Trial, First Do a Modeling StudyWietske Kievit, Alfons A den Broeder
Nederlands Tijdschrift Voor Geneeskunde|August 15, 2015
[Serious infection due to biologicals: risk only mildly elevated in patients with rheumatoid arthritis]Alfons A den Broeder, Henk J Schers
Best Practice & Research. Clinical Rheumatology|December 25, 2015
Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilarsThasia G Woodworth, Alfons A den Broeder
Best Practice & Research. Clinical Rheumatology|December 25, 2015
PrefaceAlfons A den Broeder, Thasia G Woodworth
The Journal of Rheumatology|February 4, 2014
Measuring flares in rheumatoid arthritis. (Why) do we need validated criteria?Aatke van der Maas, Alfons A den Broeder
Rheumatology Advances in Practice|March 11, 2021
(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challengesAlfons A den Broeder, Nathan den Broeder, Lise M Verhoef
Annals of the Rheumatic Diseases|November 3, 2017
Comment on l'Ami <i>et al</i> titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'Alfons A den Broeder, Bart J F van den Bemt
Annals of the Rheumatic Diseases|October 1, 2013
Biologic discontinuation studies: a systematic review of methods; comment on the article by Yoshida et alAatke van der Maas, Noortje van Herwaarden, Alfons A den Broeder
Nederlands Tijdschrift Voor Geneeskunde|March 15, 2023
[Methotrexate to prevent progression to rheumatoid arthritis?]Alfons A den Broeder, Noortje van Herwaarden, Maike H M Wientjes
Pageof 17

Showing results (1-10 of 166) with videos related to

Sort By:
Pageof 17
Best Practice & Research. Clinical Rheumatology|December 25, 2015
De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?Bruno Fautrel, Alfons A Den Broeder
The Journal of Rheumatology|March 2, 2021
If You Want to Perform a Cost-effectiveness Trial, First Do a Modeling StudyWietske Kievit, Alfons A den Broeder
Nederlands Tijdschrift Voor Geneeskunde|August 15, 2015
[Serious infection due to biologicals: risk only mildly elevated in patients with rheumatoid arthritis]Alfons A den Broeder, Henk J Schers
Best Practice & Research. Clinical Rheumatology|December 25, 2015
Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilarsThasia G Woodworth, Alfons A den Broeder
Best Practice & Research. Clinical Rheumatology|December 25, 2015
PrefaceAlfons A den Broeder, Thasia G Woodworth
The Journal of Rheumatology|February 4, 2014
Measuring flares in rheumatoid arthritis. (Why) do we need validated criteria?Aatke van der Maas, Alfons A den Broeder
Rheumatology Advances in Practice|March 11, 2021
(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challengesAlfons A den Broeder, Nathan den Broeder, Lise M Verhoef
Annals of the Rheumatic Diseases|November 3, 2017
Comment on l'Ami <i>et al</i> titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'Alfons A den Broeder, Bart J F van den Bemt
Annals of the Rheumatic Diseases|October 1, 2013
Biologic discontinuation studies: a systematic review of methods; comment on the article by Yoshida et alAatke van der Maas, Noortje van Herwaarden, Alfons A den Broeder
Nederlands Tijdschrift Voor Geneeskunde|March 15, 2023
[Methotrexate to prevent progression to rheumatoid arthritis?]Alfons A den Broeder, Noortje van Herwaarden, Maike H M Wientjes
Pageof 17